Semaglutide Reduces How Much Rats Eat but Makes Limited Food Rewards More Motivating
Chronic semaglutide in rats reduced overall food intake but paradoxically increased motivation for limited food rewards and food-associated cues.
Quick Facts
What This Study Found
Chronic semaglutide treatment in rats created a surprising split in behavior: while it reduced overall food consumption (both free food reward and regular chow), it actually increased the motivational value of limited food rewards and food-associated cues. Semaglutide-treated rats worked harder on a progressive ratio schedule to earn food and responded more for a food-paired cue during conditioned reinforcement testing.
Importantly, semaglutide did not alter the acquisition or expression of Pavlovian conditioned approach behavior itself. The dissociation — eating less overall but wanting food more intensely when it's limited — suggests semaglutide doesn't simply suppress all food motivation but rather reshapes the relationship between reward value and availability.
Key Numbers
Chronic administration · male and female rats · enhanced conditioned reinforcement responding · increased progressive ratio responding · reduced free food consumption · reduced chow intake
How They Did This
Researchers chronically administered semaglutide to male and female rats and assessed behavior using Pavlovian conditioned approach (PavCA), conditioned reinforcement tests, progressive ratio schedules for food reward, and ad libitum food consumption measures. Vehicle-treated rats served as controls.
Why This Research Matters
This challenges the simple narrative that GLP-1 drugs just reduce appetite. While semaglutide clearly decreases how much rats eat when food is freely available, it simultaneously amplifies how motivating a small, limited food reward becomes. This has implications for understanding why some patients on GLP-1 drugs may still experience intense food cravings in certain contexts, and how these drugs interact with the brain's reward system.
The Bigger Picture
Most research on GLP-1 drugs focuses on their ability to reduce food intake and body weight. This study highlights that the motivational effects are more complex — semaglutide may actually amplify the reward value of limited food. Understanding this dissociation is critical for predicting how patients behave around food in different contexts and may help explain why some people on these drugs still experience strong food cravings.
What This Study Doesn't Tell Us
This is a preprint (bioRxiv) that has not yet undergone peer review. The study was conducted in rats, and the translation of incentive salience measures to human food motivation is uncertain. Specific dosing details and sample sizes are not provided in the abstract.
Questions This Raises
- ?Does this enhanced motivation for limited food rewards translate to human behavior — could it explain cravings during portion-controlled dieting?
- ?Do different GLP-1 receptor agonists (tirzepatide, liraglutide) show the same dissociation between consumption and motivation?
- ?Could this amplified cue-responsiveness pose challenges for patients in food-rich environments despite reduced overall intake?
Trust & Context
- Key Stat:
- Eat less, want more Chronic semaglutide reduced free food intake but increased effort rats would exert for limited food rewards — revealing a dissociation between consumption and motivation
- Evidence Grade:
- This is a well-designed animal study using multiple behavioral measures, but it is a preprint that has not yet been peer-reviewed. The findings are preclinical and may not directly translate to human behavior.
- Study Age:
- Published as a 2025 preprint on bioRxiv. As a preprint, the findings should be considered preliminary until peer review is completed.
- Original Title:
- Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats.
- Published In:
- bioRxiv : the preprint server for biology (2025)
- Authors:
- Chang, Stephen E, Turner, Christopher A, Pagán, Natalia Morales, Pereira, Daniela, Kleer, Sophia, Flagel, Shelly B
- Database ID:
- RPEP-10350
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Does semaglutide just reduce appetite, or does it change how you think about food?
This study suggests it does both — but in opposite directions. Rats on chronic semaglutide ate less food overall, but they were more motivated to work for limited food rewards and more responsive to food-associated cues. Semaglutide appears to reshape food motivation rather than simply turning it off.
What does this mean for people taking Ozempic or Wegovy?
While this is a rat study and can't be directly applied to humans, it raises the possibility that GLP-1 drugs may make certain food situations — like small portions or food cues — feel more rewarding even as overall appetite decreases. This could help explain why some patients still experience strong food cravings in specific contexts.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10350APA
Chang, Stephen E; Turner, Christopher A; Pagán, Natalia Morales; Pereira, Daniela; Kleer, Sophia; Flagel, Shelly B. (2025). Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats.. bioRxiv : the preprint server for biology. https://doi.org/10.64898/2025.12.06.692775
MLA
Chang, Stephen E, et al. "Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats.." bioRxiv : the preprint server for biology, 2025. https://doi.org/10.64898/2025.12.06.692775
RethinkPeptides
RethinkPeptides Research Database. "Chronic semaglutide treatment enhances the incentive motivat..." RPEP-10350. Retrieved from https://rethinkpeptides.com/research/chang-2025-chronic-semaglutide-treatment-enhances
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.